-
公开(公告)号：US20150056182A1
公开(公告)日：2015-02-26
申请号：US14361013
申请日：2012-11-30
发明人： Tomoyuki Igawa , Naoka Hironiwa
CPC分类号： C07K16/4291 , A61K2039/505 , C07K16/248 , C07K16/303 , C07K16/4283 , C07K2317/31 , C07K2317/52 , C07K2317/92 , C07K2317/94 , G01N33/686 , G01N2500/04
摘要： The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved.
摘要翻译： 本发明人发现通过形成包含含有两个或多个抗原结合单元（表位）和两个或更多个抗原结合分子（例如抗体）的抗原的大的免疫复合物，从包含两种或更多种抗原性的抗原的血浆中消除 装订单位可以加速。 另外，通过使用该特性，通过进一步使用具有离子依赖性抗原结合活性的抗原结合分子，能够进一步促进抗原的消除，能够解决上述问题。
-
公开(公告)号：US20140199294A1
公开(公告)日：2014-07-17
申请号：US14127576
申请日：2012-06-29
发明人： Futa Mimoto , Taichi Kuramochi , Tomoyuki Igawa , Meiri Kawazoe , Hitoshi Katada , Hirotake Shiraiwa , Shojiro Kadono
IPC分类号： C07K16/46 , G01N33/566 , C07K1/107
CPC分类号： C07K16/46 , C07K1/1075 , C07K16/00 , C07K16/18 , C07K16/22 , C07K16/2866 , C07K16/30 , C07K16/303 , C07K16/36 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/92 , C07K2317/94 , G01N33/566
摘要： The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.
摘要翻译： 本发明人产生了具有由具有不同氨基酸序列的两个多肽（第一多肽和第二多肽）形成的Fc区的异二聚化多肽，并且成功地产生含有具有改善的Fc区功能的Fc区的异二聚化多肽， 其中Fc区由常规技术仅由第一多肽或仅第二多肽组成的同二聚体。
-
103.发明申请ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY 有权抗原结合分子能够绑定到两个或更多的抗原分子重复公开(公告)号：US20130303396A1
公开(公告)日：2013-11-14
申请号：US13889484
申请日：2013-05-08
发明人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
CPC分类号： C12N15/1037 , A61K39/12 , A61K39/145 , A61K2039/505 , A61K2039/544 , A61K2039/545 , A61K2039/552 , C07K16/244 , C07K16/248 , C07K16/2866 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C12N2760/16111 , C12N2760/16134 , C12N2770/20071 , G01N33/6854 , G01N2500/00
摘要： The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
摘要翻译： 本发明人发现，与血浆pH值相比，在早期内体体内具有较弱抗原结合活性的抗体能够用单一抗体分子与多个抗原分子结合，血浆半衰期长 改善其与抗原结合的时间持续时间。
-
公开(公告)号：US20240294653A1
公开(公告)日：2024-09-05
申请号：US18661829
申请日：2024-05-13
发明人： Taichi Kuramochi , Keiko Kasutani , Souhei Ohyama , Hiroyuki Tsunoda , Tomoyuki Igawa , Tatsuhiko Tachibana , Hirotake Shiraiwa , Keiko Esaki
CPC分类号： C07K16/2866 , G01N33/6869 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N2333/7155
摘要： The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.
-
105.发明公开公开(公告)号：US20240270846A1
公开(公告)日：2024-08-15
申请号：US18436917
申请日：2024-02-08
发明人： Shun Shimizu , Shu Wen Samantha Ho , Naoka Hironiwa , Mika Sakurai , Taro Miyazaki , Tomoyuki Igawa
CPC分类号： C07K16/2809 , C07K16/2863 , C07K16/2878 , C07K16/303 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/71 , C07K2317/75 , C07K2317/92 , C40B30/04
摘要： Antigen-binding domains that are capable of binding to CD3 and CD137 but do not bind to CD3 and CD137 at the same time and methods of using the same are provided. Methods to obtain antigen binding domains which bind to two or more different antigens more efficiently are also provided.
-
106.发明授权公开(公告)号：US11851476B2
公开(公告)日：2023-12-26
申请号：US14351654
申请日：2012-10-31
CPC分类号： C07K16/00 , C07K16/2866 , C07K16/303 , C07K16/468 , C07K2317/31 , C07K2317/522
摘要： It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain.
-
107.发明授权公开(公告)号：US11827699B2
公开(公告)日：2023-11-28
申请号：US16028140
申请日：2018-07-05
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Shigero Tamba , Takehisa Kitazawa , Takeshi Baba , Yoshinao Ruike , Junichi Nezu
CPC分类号： C07K16/24 , C07K16/00 , C07K16/18 , C07K16/22 , C07K16/248 , C07K16/2866 , A61K2039/505 , C07K2317/20 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/64 , C07K2317/70 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.
-
公开(公告)号：US11718678B2
公开(公告)日：2023-08-08
申请号：US16806027
申请日：2020-03-02
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Kenta Haraya , Yuki Iwayanagi , Tatsuhiko Tachibana , Futa Mimoto , Taichi Kuramochi , Hitoshi Katada , Shojiro Kadono
CPC分类号： C07K16/2866 , C07K16/08 , C07K16/18 , C07K16/303 , C07K2317/524 , C07K2317/72
摘要： The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fcγ receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
-
109.发明公开公开(公告)号：US20230212315A1
公开(公告)日：2023-07-06
申请号：US18081874
申请日：2022-12-15
发明人： Tomoyuki Igawa , Zenjiro Sampei , Tetsuo Kojima , Tetsuhiro Soeda , Atsushi Muto , Takehisa Kitazawa , Yukiko Nishida , Chifumi Imai , Tsukasa Suzuki , Kazutaka Yoshihashi
CPC分类号： C07K16/40 , C07K16/36 , C07K2317/31 , C07K2317/75 , C07K2317/76 , C07K2317/56 , C07K2317/565 , C07K2317/94 , C07K2317/51
摘要： Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
-
公开(公告)号：US20230183363A1
公开(公告)日：2023-06-15
申请号：US17975865
申请日：2022-10-28
发明人： Taichi Kuramochi , Keiko Kasutani , Souhei Ohyama , Hiroyuki Tsunoda , Tomoyuki Igawa , Tatsuhiko Tachibana , Hirotake Shiraiwa , Keiko Esaki
CPC分类号： C07K16/2866 , G01N33/6869 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , C07K2317/76 , A61K2039/505
摘要： The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.
-
-
-
-
-
-
-
-
-
搜索结果
194 条记录 (耗时 0.039 秒)
